ALSO NOTED: Novo Nordisk, Pfizer settle insulin suit; Perrigo gets OK for generic heartburn drug;

> Now that Pfizer has pulled Exubera off the market, Novo Nordisk has settled a patent lawsuit with the company over the inhaled insulin product. Novo Nordisk had alleged that Exubera was based on its own inhaled insulin treatment, which hasn't yet reached market. Release

> Perrigo says the FDA gave final approval to an over-the-counter, generic heartburn treatment the company will market in partnership with Dexcel Pharma. Report

> Hikma Pharmaceuticals has inked a deal to buy Arab Pharmaceutical Manufacturing for $163.6 million. Report

> Bristol-Myers Squibb hired computer systems giant EDS to manage its IT in the Americas and Asia. Report

> At an R&D day for analysts and investors, AstraZeneca is filling in some of the details on its move to merge two recent biotech purchases--MedImmune and Cambridge Antibody Technology (CAT). Report

> Several big developers will take the stage at the American Society of Hematology meeting to provide updates on a string of new blood thinners that are in the clinic. Report

> Trend spotter alert: GlaxoSmithKline's newly announced $1.4 billion partnership pact with OncoMed delivers fresh evidence of just how hot antibodies and the cancer field are these days. Report

> When it comes to government spending on medical research, the EU is far behind the U.S. And some of the leaders in the field say it's time to catch up--fast. Report

And Finally... Only one plan in the entire U.S. will cover the so-called doughnut hole in Medicare drug coverage this year. Report

Suggested Articles

Doctors fear that the only drug approved to prevent preterm birth will no longer be available after an FDA advisory committees vote in October.

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.